basic fibroblast growth factor  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    Fibroblast Growth Factor basic Recombinant Protein
    Description:
    Fibroblast Growth Factor basic Recombinant Protein for Ctrl
    Catalog Number:
    rp10915
    Price:
    None
    Category:
    Proteins Enzymes Peptides
    Buy from Supplier


    Structured Review

    Thermo Fisher basic fibroblast growth factor
    Fibroblast Growth Factor basic Recombinant Protein for Ctrl
    https://www.bioz.com/result/basic fibroblast growth factor/product/Thermo Fisher
    Average 99 stars, based on 366 article reviews
    Price from $9.99 to $1999.99
    basic fibroblast growth factor - by Bioz Stars, 2020-11
    99/100 stars

    Images

    Related Articles

    Multiplex Assay:

    Article Title: Attenuation of Hind-Limb Ischemia in Mice with Endothelial-Like Cells Derived from Different Sources of Human Stem Cells
    Article Snippet: .. Cytokine Release Conditioned medium was obtained by cultivating 1×105 hiPSC-1-EC, hiPSC-2-EC, hESC-EC, BM-EC and HUVEC with basal EBM2 medium (without supplement) for 5 days under normoxic (21% O2 , 5% CO2 ) or hypoxic (0.5% O2 , 5% CO2 ) condition using the BioSpherix OxyCycler C42 system (BioSpherix, Redfield, NY) and subjected to cytokine analysis: epidermal growth factor (EGF), basic fibroblast growth factor (FGF-B), hepatocyte growth factor (HGF), leptin, VEGF, placental growth factor (PIGF) and stromal derived factor-1 (SDF-1); adhesion molecules including, ICAM1 and vascular cell adhesion molecule (VCAM) using Procarta multiplex bead-based immunoassay kit (Affymetrix, Fremont, CA) according to manufacturer’s instructions. .. Data acquisition and analysis were done using Bio-Plex Manager software version 4.1.1.

    Knock-Out:

    Article Title: Generation and Proteome Profiling of PBMC-Originated, iPSC-Derived Corneal Endothelial Cells
    Article Snippet: .. Subsequently, the cells were transferred to mouse embryonic fibroblast–coated plates for 3 days with complete medium and finally transferred to Dulbecco's modified Eagle's medium-F12 (DMEM-F12) supplemented with 20% knockout serum replacement (KSR; Life Technologies) and 20 ng/mL basic fibroblast growth factor (bFGF; Life Technologies) until an embryonic stem cell–like colony was formed. .. Embryonic stem cell–like putative iPSC colonies were selected and cultured on a Matrigel-coated (Corning) plate in mTeSR1 medium for characterization.

    Article Title: The DEAD-box RNA-binding protein DDX6 regulates parental RNA decay for cellular reprogramming to pluripotency
    Article Snippet: .. On the next day, cells were reprogrammed using CytoTune version 1.0 or 2.0. (ID Pharma Co., Ltd., Ibaraki, Japan) 48 h after infection, medium was replaced with iPSC culture medium, Knockout DMEM, 20% Knockout serum replacement (KSR), GlutaMax, non-essential amino acids, pyruvic acids, and 20 ng/ml basic fibroblast growth factor (bFGF; Thermo Fisher Scientific Inc.). .. Cells were observed and images were captured using an Olympus IX71 inverted microscope (Tokyo, Japan).

    Bead-based Assay:

    Article Title: Attenuation of Hind-Limb Ischemia in Mice with Endothelial-Like Cells Derived from Different Sources of Human Stem Cells
    Article Snippet: .. Cytokine Release Conditioned medium was obtained by cultivating 1×105 hiPSC-1-EC, hiPSC-2-EC, hESC-EC, BM-EC and HUVEC with basal EBM2 medium (without supplement) for 5 days under normoxic (21% O2 , 5% CO2 ) or hypoxic (0.5% O2 , 5% CO2 ) condition using the BioSpherix OxyCycler C42 system (BioSpherix, Redfield, NY) and subjected to cytokine analysis: epidermal growth factor (EGF), basic fibroblast growth factor (FGF-B), hepatocyte growth factor (HGF), leptin, VEGF, placental growth factor (PIGF) and stromal derived factor-1 (SDF-1); adhesion molecules including, ICAM1 and vascular cell adhesion molecule (VCAM) using Procarta multiplex bead-based immunoassay kit (Affymetrix, Fremont, CA) according to manufacturer’s instructions. .. Data acquisition and analysis were done using Bio-Plex Manager software version 4.1.1.

    Cell Culture:

    Article Title: Functional invadopodia formed in glioblastoma stem cells are important regulators of tumor angiogenesis
    Article Snippet: .. Dissociated cells were cultured in Neurobasal medium (NBE) supplemented with 20 ng/mL of basic fibroblast growth factor (bFGF, Invitrogen), 20 ng/mL of epidermal growth factor (EGF, Invitrogen) and the culture supplements N2 (100×, Invitrogen) and B27 (50×, Invitrogen). .. GSC cells positive for the surface marker CD133 were isolated by magnetic cell sorting.

    Article Title: Human Adipose Mesenchymal Stem Cells Show More Efficient Angiogenesis Promotion on Endothelial Colony-Forming Cells than Umbilical Cord and Endometrium
    Article Snippet: .. SVF was cultured in Dulbecco's modified Eagle's medium-F12 (DMEM/F-12) containing 10 ng/ml basic fibroblast growth factor (bFGF, GIBCO, USA) and 10% fetal bovine serum (FBS). .. Umbilical cords (UC) were obtained from healthy infants under aseptic conditions (The Third Xiangya Hospital of Central South University) and were processed within 24 h. After the removal of blood vessels, the tissue was minced in 0.5 cm3 large pieces and digested with the digestion solution mentioned above for 16 h at 37°C.

    Article Title: Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness
    Article Snippet: .. Cells were cultured in serum-free DMEM/F12 medium containing 5 μg/mL insulin (Sigma-Aldrich, St. Louis, MO, USA), 0.4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA), 10 ng/mL basic fibroblast growth factor (Invitrogen, Waltham, MA, USA), and 20 ng/mL human recombinant epidermal growth factor (Invitrogen, Waltham, MA, USA) and observed after 14 days. ..

    Infection:

    Article Title: The DEAD-box RNA-binding protein DDX6 regulates parental RNA decay for cellular reprogramming to pluripotency
    Article Snippet: .. On the next day, cells were reprogrammed using CytoTune version 1.0 or 2.0. (ID Pharma Co., Ltd., Ibaraki, Japan) 48 h after infection, medium was replaced with iPSC culture medium, Knockout DMEM, 20% Knockout serum replacement (KSR), GlutaMax, non-essential amino acids, pyruvic acids, and 20 ng/ml basic fibroblast growth factor (bFGF; Thermo Fisher Scientific Inc.). .. Cells were observed and images were captured using an Olympus IX71 inverted microscope (Tokyo, Japan).

    Modification:

    Article Title: The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype
    Article Snippet: .. AccutaseTM was purchased from Innovative Cell Technologies Inc.; fibroblast growth factor-basic (β-FGF) was purchased from GIBCO; epidermal growth factor (EGF) was purchased from PeproTech Inc.; mouse monoclonal antibodies (Alexa Fluor® 555 Conjugate) against glial fibrillary acidic protein, MAP-2, Sox2, and β-actin were purchased from Cell Signaling Technology Inc. Dulbecco’s modified Eagle’s medium/Ham’s F-12 (DMEM/F-12) was purchase from Lonza. .. SN50 was purchased from Enzo Life Sciences Inc.

    Article Title: Generation and Proteome Profiling of PBMC-Originated, iPSC-Derived Corneal Endothelial Cells
    Article Snippet: .. Subsequently, the cells were transferred to mouse embryonic fibroblast–coated plates for 3 days with complete medium and finally transferred to Dulbecco's modified Eagle's medium-F12 (DMEM-F12) supplemented with 20% knockout serum replacement (KSR; Life Technologies) and 20 ng/mL basic fibroblast growth factor (bFGF; Life Technologies) until an embryonic stem cell–like colony was formed. .. Embryonic stem cell–like putative iPSC colonies were selected and cultured on a Matrigel-coated (Corning) plate in mTeSR1 medium for characterization.

    Article Title: Human Adipose Mesenchymal Stem Cells Show More Efficient Angiogenesis Promotion on Endothelial Colony-Forming Cells than Umbilical Cord and Endometrium
    Article Snippet: .. SVF was cultured in Dulbecco's modified Eagle's medium-F12 (DMEM/F-12) containing 10 ng/ml basic fibroblast growth factor (bFGF, GIBCO, USA) and 10% fetal bovine serum (FBS). .. Umbilical cords (UC) were obtained from healthy infants under aseptic conditions (The Third Xiangya Hospital of Central South University) and were processed within 24 h. After the removal of blood vessels, the tissue was minced in 0.5 cm3 large pieces and digested with the digestion solution mentioned above for 16 h at 37°C.

    Recombinant:

    Article Title: Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness
    Article Snippet: .. Cells were cultured in serum-free DMEM/F12 medium containing 5 μg/mL insulin (Sigma-Aldrich, St. Louis, MO, USA), 0.4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA), 10 ng/mL basic fibroblast growth factor (Invitrogen, Waltham, MA, USA), and 20 ng/mL human recombinant epidermal growth factor (Invitrogen, Waltham, MA, USA) and observed after 14 days. ..

    Derivative Assay:

    Article Title: Attenuation of Hind-Limb Ischemia in Mice with Endothelial-Like Cells Derived from Different Sources of Human Stem Cells
    Article Snippet: .. Cytokine Release Conditioned medium was obtained by cultivating 1×105 hiPSC-1-EC, hiPSC-2-EC, hESC-EC, BM-EC and HUVEC with basal EBM2 medium (without supplement) for 5 days under normoxic (21% O2 , 5% CO2 ) or hypoxic (0.5% O2 , 5% CO2 ) condition using the BioSpherix OxyCycler C42 system (BioSpherix, Redfield, NY) and subjected to cytokine analysis: epidermal growth factor (EGF), basic fibroblast growth factor (FGF-B), hepatocyte growth factor (HGF), leptin, VEGF, placental growth factor (PIGF) and stromal derived factor-1 (SDF-1); adhesion molecules including, ICAM1 and vascular cell adhesion molecule (VCAM) using Procarta multiplex bead-based immunoassay kit (Affymetrix, Fremont, CA) according to manufacturer’s instructions. .. Data acquisition and analysis were done using Bio-Plex Manager software version 4.1.1.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    Thermo Fisher gene exp fgfr2 hs01552926 m1
    Loss of <t>FGFR2</t> Impaired Self-Renewal of Breast TICs, Resulting in a Decreased TIC Pool. (A) Flow cytometry analysis of CD24 and CD29 expression for TIC and non-TIC subpopulation frequencies in shRNA-transduced primary MMTV-PyMT breast tumor cells. (B) Quantification of TIC and non-TIC subpopulation frequencies in shRNA transduced breast tumor cells determined by FACS analysis (A). Data (n = 2) represent mean ± s.d. Statistical comparison with shNT (* P
    Gene Exp Fgfr2 Hs01552926 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp fgfr2 hs01552926 m1/product/Thermo Fisher
    Average 89 stars, based on 17 article reviews
    Price from $9.99 to $1999.99
    gene exp fgfr2 hs01552926 m1 - by Bioz Stars, 2020-11
    89/100 stars
      Buy from Supplier

    99
    Thermo Fisher gene exp fgf2 hs00266645 m1
    An inhibitor of FGF or VEGF receptors eliminates the superior effect of TA-316 on imMKCL proliferation. imMKCLs cultured with rhTPO (50 ng/mL), TA-316 (200 ng/mL), eltrombopag (1000 ng/mL), or DMSO (0.05%). (A) Cells were collected on day 11 (genes on). mRNA expressions of VEGFA and <t>FGF2</t> (genes on) were evaluated using Taqman PCR assays. GAPDH served as an internal control. (B) FGFR antagonist PD173074 (100 nM; WAKO), VEGFR antagonist axitinib (5 nM; Toronto Research Chemicals, Toronto, Canada), or epithelial growth factor receptor antagonist gefitinib (1 μM, Santa Cruz Biotechnology, Dallas, TX) was added to the imMKCLs, which were cultured with TA-316 (200 ng/mL) for 4 days (genes on). Cell proliferation was assessed based on 0.4% Trypan blue staining (Thermo Fisher Scientific). Data represent the mean and SD; * P
    Gene Exp Fgf2 Hs00266645 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp fgf2 hs00266645 m1/product/Thermo Fisher
    Average 99 stars, based on 16 article reviews
    Price from $9.99 to $1999.99
    gene exp fgf2 hs00266645 m1 - by Bioz Stars, 2020-11
    99/100 stars
      Buy from Supplier

    88
    Thermo Fisher gene exp fgfr2 mm01275521 m1
    MEK1 activity rescues the loss of <t>FGFR2</t> in vaginal epithelial differentiation. A, IF analysis of pERK1/2 in the vagina of Fgfr2 cHet and cKO mice at PD2. pERK1/2 (green) was costained with K14 (red). The loss of FGFR2 reduced ERK activity in the cervical/vaginal
    Gene Exp Fgfr2 Mm01275521 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp fgfr2 mm01275521 m1/product/Thermo Fisher
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    gene exp fgfr2 mm01275521 m1 - by Bioz Stars, 2020-11
    88/100 stars
      Buy from Supplier

    Image Search Results


    Loss of FGFR2 Impaired Self-Renewal of Breast TICs, Resulting in a Decreased TIC Pool. (A) Flow cytometry analysis of CD24 and CD29 expression for TIC and non-TIC subpopulation frequencies in shRNA-transduced primary MMTV-PyMT breast tumor cells. (B) Quantification of TIC and non-TIC subpopulation frequencies in shRNA transduced breast tumor cells determined by FACS analysis (A). Data (n = 2) represent mean ± s.d. Statistical comparison with shNT (* P

    Journal: PLoS ONE

    Article Title: FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

    doi: 10.1371/journal.pone.0051671

    Figure Lengend Snippet: Loss of FGFR2 Impaired Self-Renewal of Breast TICs, Resulting in a Decreased TIC Pool. (A) Flow cytometry analysis of CD24 and CD29 expression for TIC and non-TIC subpopulation frequencies in shRNA-transduced primary MMTV-PyMT breast tumor cells. (B) Quantification of TIC and non-TIC subpopulation frequencies in shRNA transduced breast tumor cells determined by FACS analysis (A). Data (n = 2) represent mean ± s.d. Statistical comparison with shNT (* P

    Article Snippet: The following Taqman Gene Expression Assays (Applied Biosystems) were used: mouse FGFR2 (Mm00438941_m1), human FGFR2 (Hs01552926_m1), mouse ACTB (beta actin) endogenous control (4352341E), human ACTB (beta actin) endogenous control (4326315E).

    Techniques: Flow Cytometry, Cytometry, Expressing, shRNA, FACS

    Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. (A) Antitumor activity of FGFR inhibitor, TKI258. Daily oral administration of TKI258 at 50 mg/kg was initiated in tumor-bearing NOD/SCID mice (n = 5 per group) when the MMTV-PyMT breast tumors reached ∼150 mm 3 in volume. P value at day 32 is indicated. (B) Reduced phosphorylation of FGFR2 and Erk1/2 upon treatment of breast tumors with TKI258. Breast tumors were collected at predose, 4 and 24 hours after administration of a single oral dose of TKI258. Tumors were homogenized, immunoprecipitated for FGFR2 and immunoblotted with anti-phosphotyrosine to evaluate phosphorylation of FGFR2. The membranes were reprobed to evaluate total level of FGFR2 protein. (C) Flow cytometry analysis of CD24 and CD29 expression for TIC and non-TIC subpopulation frequencies in TKI258- or control-treated breast tumors. (D) Quantification of TIC and non-TIC subpopulations in TKI258- or control-treated breast tumors determined by flow cytometry analysis (C). Data (n = 3) represent mean ± SEM. Statistical comparison with control treatment (* P

    Journal: PLoS ONE

    Article Title: FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

    doi: 10.1371/journal.pone.0051671

    Figure Lengend Snippet: Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. (A) Antitumor activity of FGFR inhibitor, TKI258. Daily oral administration of TKI258 at 50 mg/kg was initiated in tumor-bearing NOD/SCID mice (n = 5 per group) when the MMTV-PyMT breast tumors reached ∼150 mm 3 in volume. P value at day 32 is indicated. (B) Reduced phosphorylation of FGFR2 and Erk1/2 upon treatment of breast tumors with TKI258. Breast tumors were collected at predose, 4 and 24 hours after administration of a single oral dose of TKI258. Tumors were homogenized, immunoprecipitated for FGFR2 and immunoblotted with anti-phosphotyrosine to evaluate phosphorylation of FGFR2. The membranes were reprobed to evaluate total level of FGFR2 protein. (C) Flow cytometry analysis of CD24 and CD29 expression for TIC and non-TIC subpopulation frequencies in TKI258- or control-treated breast tumors. (D) Quantification of TIC and non-TIC subpopulations in TKI258- or control-treated breast tumors determined by flow cytometry analysis (C). Data (n = 3) represent mean ± SEM. Statistical comparison with control treatment (* P

    Article Snippet: The following Taqman Gene Expression Assays (Applied Biosystems) were used: mouse FGFR2 (Mm00438941_m1), human FGFR2 (Hs01552926_m1), mouse ACTB (beta actin) endogenous control (4352341E), human ACTB (beta actin) endogenous control (4326315E).

    Techniques: Activity Assay, In Vivo, Mouse Assay, Immunoprecipitation, Flow Cytometry, Cytometry, Expressing

    Gene Expression Profiles of Breast TICs and Non-TICs Revealed that FGFR2 Is Preferentially Expressed in Breast TICs. (A) Heat map of microarray analysis depicting the expression levels of the mRNAs of 7 genes that are significantly upregulated in the TIC population compared with the three other non-TIC populations. RNA was prepared from the four FACS-sorted populations of primary MMTV-PyMT breast tumors. Red and green indicate high and low mRNA expression levels, respectively. The expression values were normalized by Z score. (B) The expression levels of the mRNAs of 7 genes in TICs and non-TICs, as determined by quantitative real-time PCR. cDNA isolated from non-TICs was used to normalize data for each primer of gene and generate RQ (relative quantity). (C) The expression levels FGFR2 protein in the subpopulations by flow cytometry. This figure represents a typical result of three independent experiments. Dashed line shows isotype labeling.

    Journal: PLoS ONE

    Article Title: FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

    doi: 10.1371/journal.pone.0051671

    Figure Lengend Snippet: Gene Expression Profiles of Breast TICs and Non-TICs Revealed that FGFR2 Is Preferentially Expressed in Breast TICs. (A) Heat map of microarray analysis depicting the expression levels of the mRNAs of 7 genes that are significantly upregulated in the TIC population compared with the three other non-TIC populations. RNA was prepared from the four FACS-sorted populations of primary MMTV-PyMT breast tumors. Red and green indicate high and low mRNA expression levels, respectively. The expression values were normalized by Z score. (B) The expression levels of the mRNAs of 7 genes in TICs and non-TICs, as determined by quantitative real-time PCR. cDNA isolated from non-TICs was used to normalize data for each primer of gene and generate RQ (relative quantity). (C) The expression levels FGFR2 protein in the subpopulations by flow cytometry. This figure represents a typical result of three independent experiments. Dashed line shows isotype labeling.

    Article Snippet: The following Taqman Gene Expression Assays (Applied Biosystems) were used: mouse FGFR2 (Mm00438941_m1), human FGFR2 (Hs01552926_m1), mouse ACTB (beta actin) endogenous control (4352341E), human ACTB (beta actin) endogenous control (4326315E).

    Techniques: Expressing, Microarray, FACS, Real-time Polymerase Chain Reaction, Isolation, Flow Cytometry, Cytometry, Labeling

    Human Breast TICs Were Enriched in FGFR2+ Population that Was Sufficient to Initiate Tumor Growth. (A) The expression levels of FGFR2 mRNA in patient-derived breast tumors. Quantitative real-time PCR was performed using cDNA generated from RNA isolated from 26 primary human breast cancer specimens. cDNA isolated from a normal breast tissue was used to normalize data and generate RQ. (B) Flow cytometry analysis of FGFR2 protein expression in primary human breast tumors. High (BT5 and BT12) or low level (BT8 and BT25) of FGFR2 protein corresponded to high or low level of FGFR2 mRNA (A). This figure represents a typical result of three independent experiments. Dashed line shows an unstained control for each tumor sample. (C) Effect of FGFR2 expression on primary human breast tumor growth. FGFR2−overexpressing primary human breast tumor cells (BT5) were FACS sorted based on the expression of FGFR2. The two isolated populations (FGFR+ and FGFR2−) were injected in the mammary fat pad of the NOD/SCID mice (n = 5 per group). P value at day 70 is indicated. Data represent mean ± SEM. (D) Flow cytometry analysis of ALDH activity in FGFR2+ and FGFR2− subpopulations of BT5 tumors. Higher ALDH activity was found in the FGFR2+ population compared to the FGFR2− population. Dashed line shows a specific inhibitor of ALDH (DEAB)-treated labeling.

    Journal: PLoS ONE

    Article Title: FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

    doi: 10.1371/journal.pone.0051671

    Figure Lengend Snippet: Human Breast TICs Were Enriched in FGFR2+ Population that Was Sufficient to Initiate Tumor Growth. (A) The expression levels of FGFR2 mRNA in patient-derived breast tumors. Quantitative real-time PCR was performed using cDNA generated from RNA isolated from 26 primary human breast cancer specimens. cDNA isolated from a normal breast tissue was used to normalize data and generate RQ. (B) Flow cytometry analysis of FGFR2 protein expression in primary human breast tumors. High (BT5 and BT12) or low level (BT8 and BT25) of FGFR2 protein corresponded to high or low level of FGFR2 mRNA (A). This figure represents a typical result of three independent experiments. Dashed line shows an unstained control for each tumor sample. (C) Effect of FGFR2 expression on primary human breast tumor growth. FGFR2−overexpressing primary human breast tumor cells (BT5) were FACS sorted based on the expression of FGFR2. The two isolated populations (FGFR+ and FGFR2−) were injected in the mammary fat pad of the NOD/SCID mice (n = 5 per group). P value at day 70 is indicated. Data represent mean ± SEM. (D) Flow cytometry analysis of ALDH activity in FGFR2+ and FGFR2− subpopulations of BT5 tumors. Higher ALDH activity was found in the FGFR2+ population compared to the FGFR2− population. Dashed line shows a specific inhibitor of ALDH (DEAB)-treated labeling.

    Article Snippet: The following Taqman Gene Expression Assays (Applied Biosystems) were used: mouse FGFR2 (Mm00438941_m1), human FGFR2 (Hs01552926_m1), mouse ACTB (beta actin) endogenous control (4352341E), human ACTB (beta actin) endogenous control (4326315E).

    Techniques: Expressing, Derivative Assay, Real-time Polymerase Chain Reaction, Generated, Isolation, Flow Cytometry, Cytometry, FACS, Injection, Mouse Assay, Activity Assay, Labeling

    Suppression of Breast Tumor Growth and Inhibition of Oncogenic Signaling by Loss of FGFR2. (A) Quantitative real-time PCR analysis of expression levels of FGFR2 mRNA in MMTV-PyMT breast tumor cells stably transduced with lentiviral shRNAs targeting FGFR2 (shFGFR2) and non-targeting shRNA (shNT). shFGFR2-2 and shFGFR2-3, targeting different regions of FGFR2 gene, were used for knockdown of FGFR2. Mock (no infection) and shNT infection were used as negative controls. (B) Reduced proliferation of breast tumor cells upon FGFR2 knockdown in vitro . Proliferation of tumor cells was determined by cell viability using CellTiter-Glo reagent (Promega). Statistical comparison with shNT (* P

    Journal: PLoS ONE

    Article Title: FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

    doi: 10.1371/journal.pone.0051671

    Figure Lengend Snippet: Suppression of Breast Tumor Growth and Inhibition of Oncogenic Signaling by Loss of FGFR2. (A) Quantitative real-time PCR analysis of expression levels of FGFR2 mRNA in MMTV-PyMT breast tumor cells stably transduced with lentiviral shRNAs targeting FGFR2 (shFGFR2) and non-targeting shRNA (shNT). shFGFR2-2 and shFGFR2-3, targeting different regions of FGFR2 gene, were used for knockdown of FGFR2. Mock (no infection) and shNT infection were used as negative controls. (B) Reduced proliferation of breast tumor cells upon FGFR2 knockdown in vitro . Proliferation of tumor cells was determined by cell viability using CellTiter-Glo reagent (Promega). Statistical comparison with shNT (* P

    Article Snippet: The following Taqman Gene Expression Assays (Applied Biosystems) were used: mouse FGFR2 (Mm00438941_m1), human FGFR2 (Hs01552926_m1), mouse ACTB (beta actin) endogenous control (4352341E), human ACTB (beta actin) endogenous control (4326315E).

    Techniques: Inhibition, Real-time Polymerase Chain Reaction, Expressing, Stable Transfection, Transduction, shRNA, Infection, In Vitro

    An inhibitor of FGF or VEGF receptors eliminates the superior effect of TA-316 on imMKCL proliferation. imMKCLs cultured with rhTPO (50 ng/mL), TA-316 (200 ng/mL), eltrombopag (1000 ng/mL), or DMSO (0.05%). (A) Cells were collected on day 11 (genes on). mRNA expressions of VEGFA and FGF2 (genes on) were evaluated using Taqman PCR assays. GAPDH served as an internal control. (B) FGFR antagonist PD173074 (100 nM; WAKO), VEGFR antagonist axitinib (5 nM; Toronto Research Chemicals, Toronto, Canada), or epithelial growth factor receptor antagonist gefitinib (1 μM, Santa Cruz Biotechnology, Dallas, TX) was added to the imMKCLs, which were cultured with TA-316 (200 ng/mL) for 4 days (genes on). Cell proliferation was assessed based on 0.4% Trypan blue staining (Thermo Fisher Scientific). Data represent the mean and SD; * P

    Journal: Blood Advances

    Article Title: Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells

    doi: 10.1182/bloodadvances.2016000844

    Figure Lengend Snippet: An inhibitor of FGF or VEGF receptors eliminates the superior effect of TA-316 on imMKCL proliferation. imMKCLs cultured with rhTPO (50 ng/mL), TA-316 (200 ng/mL), eltrombopag (1000 ng/mL), or DMSO (0.05%). (A) Cells were collected on day 11 (genes on). mRNA expressions of VEGFA and FGF2 (genes on) were evaluated using Taqman PCR assays. GAPDH served as an internal control. (B) FGFR antagonist PD173074 (100 nM; WAKO), VEGFR antagonist axitinib (5 nM; Toronto Research Chemicals, Toronto, Canada), or epithelial growth factor receptor antagonist gefitinib (1 μM, Santa Cruz Biotechnology, Dallas, TX) was added to the imMKCLs, which were cultured with TA-316 (200 ng/mL) for 4 days (genes on). Cell proliferation was assessed based on 0.4% Trypan blue staining (Thermo Fisher Scientific). Data represent the mean and SD; * P

    Article Snippet: All Taqman primers and probes were obtained from Applied Biosystems: glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs02758991_g1); GATA binding protein 1 (GATA1; Hs01085823_m1); zinc finger protein, FOG family member 1 (ZFPM1; Hs00542350_m1); nuclear factor, erythroid 2 (NFE2; Hs00232351_m1); Fli-1 proto-oncogene ETS transcription factor (FLI1; Hs00956711_m1); von Willebrand factor (VWF; Hs04397751_m1); VEGF A (VEGFA; Hs00173626_m1); and basic FGF2 (Hs00266645_m1).

    Techniques: Cell Culture, Polymerase Chain Reaction, Staining

    MEK1 activity rescues the loss of FGFR2 in vaginal epithelial differentiation. A, IF analysis of pERK1/2 in the vagina of Fgfr2 cHet and cKO mice at PD2. pERK1/2 (green) was costained with K14 (red). The loss of FGFR2 reduced ERK activity in the cervical/vaginal

    Journal: Molecular Endocrinology

    Article Title: FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct

    doi: 10.1210/me.2016-1027

    Figure Lengend Snippet: MEK1 activity rescues the loss of FGFR2 in vaginal epithelial differentiation. A, IF analysis of pERK1/2 in the vagina of Fgfr2 cHet and cKO mice at PD2. pERK1/2 (green) was costained with K14 (red). The loss of FGFR2 reduced ERK activity in the cervical/vaginal

    Article Snippet: For the quantitation of FGFs and FGFRs transcripts, TaqMan Probes were purchased from Life Technologies: Fgf1, Mm00438906_m1; Fgf7, Mm00433291_m1; Fgf9, Mm00442795_m1; Fgf10, Mm00433275_m1; Fgf13, Mm00438910_m1; Fgfr21, Mm00840165_g1; Fgfr22, Mm00445749_m1; Fgfr1, Mm00438930_m1; Fgfr2IIIb, Mm01275521_m1; Fgfr2IIIc, Mm01269938_m1; Fgfr3, Mm00433294_m1; Fgfr4, Mm01341852_m1; and Actb, Mm00607939_s1.

    Techniques: Activity Assay, Mouse Assay

    Uterine phenotypes of Fgfr2 cKO mice. A, Fgfr2 cHet and cKO uterine grafts developed uterine glands expressing FOXA2 (green). Epithelium was highlighted by pan CK (red). Scale bar, 100 μm. B, Regulation of PR (green) in Fgfr2 cHet and cKO uterine

    Journal: Molecular Endocrinology

    Article Title: FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct

    doi: 10.1210/me.2016-1027

    Figure Lengend Snippet: Uterine phenotypes of Fgfr2 cKO mice. A, Fgfr2 cHet and cKO uterine grafts developed uterine glands expressing FOXA2 (green). Epithelium was highlighted by pan CK (red). Scale bar, 100 μm. B, Regulation of PR (green) in Fgfr2 cHet and cKO uterine

    Article Snippet: For the quantitation of FGFs and FGFRs transcripts, TaqMan Probes were purchased from Life Technologies: Fgf1, Mm00438906_m1; Fgf7, Mm00433291_m1; Fgf9, Mm00442795_m1; Fgf10, Mm00433275_m1; Fgf13, Mm00438910_m1; Fgfr21, Mm00840165_g1; Fgfr22, Mm00445749_m1; Fgfr1, Mm00438930_m1; Fgfr2IIIb, Mm01275521_m1; Fgfr2IIIc, Mm01269938_m1; Fgfr3, Mm00433294_m1; Fgfr4, Mm01341852_m1; and Actb, Mm00607939_s1.

    Techniques: Mouse Assay, Expressing

    FGFR2 is essential for the commitment of MDE to vaginal epithelial cell fate. A, IF analysis of epithelial marker expression in the vaginae (Vgs) of PD4 Fgfr2 cHet and cKO mice (n ≥ 4). Vaginal epithelium of Fgfr2 cKO mice lacked the expression

    Journal: Molecular Endocrinology

    Article Title: FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct

    doi: 10.1210/me.2016-1027

    Figure Lengend Snippet: FGFR2 is essential for the commitment of MDE to vaginal epithelial cell fate. A, IF analysis of epithelial marker expression in the vaginae (Vgs) of PD4 Fgfr2 cHet and cKO mice (n ≥ 4). Vaginal epithelium of Fgfr2 cKO mice lacked the expression

    Article Snippet: For the quantitation of FGFs and FGFRs transcripts, TaqMan Probes were purchased from Life Technologies: Fgf1, Mm00438906_m1; Fgf7, Mm00433291_m1; Fgf9, Mm00442795_m1; Fgf10, Mm00433275_m1; Fgf13, Mm00438910_m1; Fgfr21, Mm00840165_g1; Fgfr22, Mm00445749_m1; Fgfr1, Mm00438930_m1; Fgfr2IIIb, Mm01275521_m1; Fgfr2IIIc, Mm01269938_m1; Fgfr3, Mm00433294_m1; Fgfr4, Mm01341852_m1; and Actb, Mm00607939_s1.

    Techniques: Marker, Expressing, Mouse Assay